Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.

Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
Provided are methods for detecting and treating disease states, including cancer, diabetes, fibrosis, and autoimmune diseases, by detecting increased mechanical modulus, or stiffness, or targeting tissues having increased mechanical modulus, or stiffness. Practicing these methods provides specific and localized detection assays and therapies for these disease states.

Therapeutic antibodies and their uses
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease).

Chimeric and humanized anti-histone antibodies
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.

Diagnosis of a novel autoimmune disease
Polypeptides including neurochondrin and autoantibodies binding to polypeptides including neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided.

Glucose uptake inhibitors
Provided herein are compounds that modulate glucose uptake activity and are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as glut1 and other glut family members/alternative hexose transporters.

Protein particles comprising disulfide crosslinkers and uses related thereto
This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.

Methods for diagnosis of sepsis
Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of biomarkers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (sirs)..

Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
Bispecific antibodies are provided that bind calcitonin gene related peptide (cgrp) and interleukin-23 (il-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both cgrp and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, psoriatic arthritis (psa) and ankylosing spondylitis (as)..

Compositions and methods for the depletion of cd137+ cells
The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind cd137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions..

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..

Azetidine derivative, preparation method therefor, and use thereof

The present invention relates to an azetidine derivative for use as a janus kinase (jak) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of jak-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.. .

Pharmaceutical composition for preventing or treating autoimmune diseases comprising cedrol or derivatives thereof, or pharmaceutically acceptable salts thereof

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of il-17a, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model.

Cosmetic composition for preventing or ameliorating hypersensitive skin comprising cedrol or derivatives thereof, or pharmaceutically acceptable salts thereof

The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of il-17a, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model.

Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases

A method for measuring anti-pad2 antibodies in a subject with an inflammatory or autoimmune disease, and to determine if the subject has a better prognosis for developing a more severe form of inflammation based on anti-pad2 antibody levels. Methods for the therapeutic use of anti-pad2 antibodies are also described..

Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose

The present disclosure involves biologically active proteins termed stradobodies and having bimodal activity. Thus, the present disclosure provides compositions and methods providing both target cell destructive and immunosuppressive activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, infectious diseases, or cancers..

Bispecific constructs and their use in the treatment of various diseases

The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .

Phosphorylcholine conjugates and uses thereof

The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation..

Method of controlling administration of cancer antigen

The present invention is directed to mammalian bi-specific t cells and methods for using these bi-specific t cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific t cells that express a viral antigen t cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting t-cells which express viral antigen.

Methods for predicting flare and improving treatment of patients

In some embodiments, the present invention provides methods for predicting flare in subjects with autoimmune disease (e.g., lupus erythematosus). In some embodiments, pending flares may be reduced in severity and/or prevented from clinical manifestation in their entirety using provided methods.
Kypha, Inc.

Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in ddx39b (rs2523506) and il7r (rs6897932)

The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble interleukin 7 receptor (sil7r), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble interleukin-7 receptor (sil7r) and an amount of an rna helicase ddx39b, whereby a lower expression of ddx39b and a higher secretion of sil7r identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of rna helicase ddx39b alone or in combination with an increase in sil7r..
University Of California, Berkeley

Treating and preventing microbial infections

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, sirs or septic shock.
Snipr Biome Aps

Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

The present invention provides chimeric and humanized versions of anti-cd19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human cd19 antigen and that may mediate adcc, cdc, and/or apoptosis for the treatment of b cell diseases and disorders, such as, but not limited to, b cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (gvhd), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients..
Viela Bio, Inc.

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells

The present invention provides compositions and methods useful for promoting or reducing t-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (apc) activation.
Dana-farber Cancer Institute, Inc.

Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets

Methods for detecting antigen-specific antibodies in a biological sample are described. The disclosed methods can be used for the diagnosis of a variety of autoimmune and infectious diseases.
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services

Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases

The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a cd40 or cd40l antagonist such as anti-cd40 antibody, anti-cd40l antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment..
Biogen Ma Inc.

Complement split product c4d for the treatment of inflammatory conditions

The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Medizinische Universität Wien

Treatment of autoimmune diseases

The present invention concerns treatment of autoimmune diseases with antagonists which bind to b cell surface markers, such as cd19 or cd20.. .
Biogen Inc.

Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity

Provided herein are methods and materials for treating autoimmune diseases and alloimmune diseases. Specifically, provided are a pharmaceutical composition comprising a therapeutically effective amount of a population of modified human t cells, wherein the human t cells are modified to comprise a nucleic acid sequence that encodes a chimeric antigen receptor (car) construct, wherein the car construct comprises an antigen binding domain, wherein the antigen binding domain is specific for a ligand expressed on b cells, plasma cells or plasmablasts in human patients suffering from an autoimmune disease or an alloimmune disease; and a method of treating an autoimmune or an alloimmune disease in a human patient, the method comprising: administering a pharmaceutical composition..
Regents Of The University Of Minnesota

Rna polymerase i inhibitors and uses thereof

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .
Tel Hashomer Medical Research Infrastructure And Services Ltd.

Methods of treating conditions related to the s1p1 receptor

Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (s1p1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (r)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type i diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.. .
Arena Pharmaceuticals, Inc.

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Cell penetrating peptides that inhibit irf5 nuclear localization

The invention provides inhibitors of interferon regulatory factor 5 (irf5) nuclear localization and methods of using the inhibitors to treat autoimmune diseases such as systemic lupus erythematosus (sle).. .

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Substituted amino triazoles useful as human chitinase inhibitors

Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.

Soluble mediator

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..

Treatments for autoimmune disease

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for use in the treatment of auto-immune diseases.

Composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin

The present invention relates to a composition for preventing or treating mitochondrial diseases caused by immunosuppressants, and immune diseases, containing metformin and, more specifically, to a composition for treating mitochondrial diseases caused by immunosuppressants, containing metformin; a pharmaceutical composition for preventing or treating immune diseases, containing, as active ingredients, metformin and an immunosuppressant, which is a target of rapamycin inhibitor (mtor inhibitor); and a pharmaceutical composite formulation for preventing or treating immune diseases, containing, as ingredients, metformin and a mammalian target of rapamycin inhibitor, wherein the metformin and mammalian target of rapamycin inhibitor are administered simultaneously or separately, or administered in a predetermined sequence. The composition effectively alleviates mitochondrial dysfunction, occurring as a side effect of conventional immunosuppressants, while having a more improved immunosuppressive therapeutic effect, thereby being usable in prevention and treatment of transplant rejection, autoimmune diseases, inflammatory diseases, and the like, all of which require immunosuppression..

Diagnostic s for autoimmune disease

Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.. .
Pzm Diagnostics, Llc

Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Embodiments of the present invention describe methods for modulating lgals3bp and the use of antibodies to the same in the treatment of autoimmune diseases including systemic lupus erythematosus and lupus nephritis.. .
Merck Patent Gmbh

Malt1 inhibitors and uses thereof

Provided herein are compounds of formula (i) and pharmaceutical compositions thereof, which may be useful as malt1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-hodgkin's lymphoma, diffuse large b-cell lymphoma, malt, lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of formula (i)..
Children's Medical Center Corporation

Heterocyclic compounds and uses thereof

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, egfr (including her), alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, btk, or jak, and the respective pathways.. .
Acea Biosciences Inc.

Novel compounds and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Aminopyridazinone compounds as protein kinase inhibitors

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.. .
Jiangsu Hengrui Medicine Co., Ltd.

Indolin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.. .

Indolin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.. .

Indolin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.. .

Indolin-2-one derivatives

The compounds may be used in the treatment of cns diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, huntington's disease, adhd, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.. .

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie, Inc.

Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases

Provided herein are improved compositions comprising lactoferrin and methods for modulating t cell subtypes and their activities in a subject, to improve the balance between anti-inflammatory (th2) cytokine producing cells and pro-inflammatory (th1) or th17 cells, and skew naïve t cells toward a pro-regulatory phenotype, for the treatment and/or amelioration of neurodegen erative or autoimmune diseases and disorders (e.g., inflammatory bowel disease (ibd), amyotrophic lateral sclerosis (als), alzheimers disease, cognitive decline in the elderly resulting from chronic inflammation, and/or rheumatoid arthritis (ra)).. .
Ventria Bioscience, Inc.

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Methods and compositions for gene editing in hematopoietic stem cells

The present invention relates to compositions and methods of generating modified hematopoietic stem or progenitor cells. One aspect of the invention includes a modified hematopoietic stem or progenitor cell comprising a nucleic acid capable of decreasing expression of an endogenous gene or a portion thereof, wherein the endogenous gene encodes a polypeptide comprising an antigen domain targeted by a chimeric antigen receptor (car).
The Trustees Of The University Of Pennsylvania

Compositions and methods for treatment of inflammation

The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response.
Creighton University

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Tethering cysteine residues using cyclic disulfides

Described herein are compounds and methods for tethering proteins. For example, dimers of protein x listed in table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker.
Brandeis University

An engineered ccl20 locked dimer polypeptide

The present invention provides a ccl20 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of psoriasis, inflammatory disorders and autoimmune disease.. .
The Medical College Of Wisconsin, Inc.

Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of formulae (i), (ii), (iii), (iv), (v), or (vi) for treating and/or preventing proliferative diseases (e.g.
Albert Einstein College Of Medicine, Inc.

Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases

Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of formulae (i), (ii), (iii), (iv), (v), or (vi) for treating and/or preventing proliferative diseases (e.g.
Memorial Sloan-kettering Cancer Center

Alpha and gamma-d polyglutamated antifolates and uses thereof

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or d-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).. .
L.e.a.f. Holdings Group Llc

Dna vaccines encoding heat shock proteins

A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by structural formula 1a: (i) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of structural formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a t-cell mediated autoimmune disease) in a subject in need thereof.
Karyopharm Therapeutics Inc.

Pharmaceutical composition for preventing or treating autoimmune diseases comprising thiourea derivative

The present invention relates to a novel use of a thiourea derivative and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases comprising a thiourea derivative as an active ingredient. The thiourea derivative according to the present invention can inhibit the transcription of inflammatory genes such as tnf-α, il-1β, nos2 and il-6, and also can inhibit the activity or production of th17 and increase the activity or production of a regulatory t cell (treg).
Seoul National University R & Db Foundation

Inhibition of the complement system

Agents and compounds which can be used to modulate the activity of the complement system, novel biological targets associated with such modulation, and pharmaceutical compositions, medicaments and methods of treatment for use in preventing, ameliorating or treating diseases that are characterised by inappropriate complement activity. These diseases include age-related macular degeneration (amd), meningitis, renal disease, autoimmune disease and inflammation.
Imperial Innovations Limited

Stimulation via tlr4/md-2 to reverse type 1 diabetes

Disclosed are methods and compositions for treating type i diabetes in a subject. Agents selected from a tlr4 agonist, a tlr4/md-2 agonist, or a combination thereof may be used in the disclosed methods and compositions.
University Of Cincinnati

Lactobacillus strain, composition and use thereof for treating syndromes and related complications of autoimmune diseases

The present invention is related to a lactobacillus strain, composition and use thereof for treating autoimmune disease and related complications. The composition comprises at least one isolate of lactobacillus paracasei strain gmnl-32, l.
Genmont Biotech Incorporation

Takeda Pharmaceutical Company Limited

. .

Immunologically active polypeptide

Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed..
Institute Of Arthritis Research, Llc

Antibody which specifically binds to human crth2

There is provided an anti-human crth2 antibody which has desired activity by recognizing and binding to a specific human crth2; the antibody fragment; dna which encodes the amino acid sequence of the antibody; a vector which comprises the dna; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.. .
Kyowa Hakko Kirin Co., Ltd

Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease

And pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by bruton's tyrosine kinase (btk).. .

Heterocyclic compounds useful as modulators of tnf alpha

Disclosed are compounds of formula (i) or a salt thereof, wherein: a is cr1 or n; b is cr3 or n; d is cr4 or n; l1 is —(cr7r7)m—; l2 is —(cr7r7)n—; and x, z, r1, r2, r3, r4, r5, and r6 are define herein. Also disclosed are methods of using such compounds as modulators of tnfα, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives

The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.
Eutropics Pharmaceuticals, Inc.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.

Cyclic compounds useful as modulators of tnf alpha

Disclosed are compounds of formula (i) or a salt thereof, wherein: ring a is 3- to 6-membered carbocyclic or heterocyclic ring; x is cr1 or n; y is —(cr5r5)m—; z is —(cr5r5)n—; and q, r1, r2, r3, r4, r6, r7, r8, r9, and r10 are defined herein. Also disclosed are methods of using such compounds as modulators of tnfα, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

In-vitro methods for the detection of autoimmune diseases or conditions

A method for the detection of impaired responsiveness of cd4+ t-cells to regulatory t-cells (treg), treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, ppargc1a (pgc-1α) in activated cd4+ t-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, ppargc1a (pgc-1α) in treg-resistant cd4+ t-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from treg-sensitive cd4+ t-cells from healthy controls.
Universitätsmedizin Der Johannes Gutenberg-universität Mainz

Anti-pd-1 antibodies and uses thereof

Anti-pd-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancers and autoimmune diseases..
Pharmaexplorer Limited

Pd-l1 expressing hematopoietic stem cells and uses

Embodiments disclosed here provide engineered modified hematopoietic stem cells (hscs), artificially prostaglandin e2 (pge2)-stimulated hscs, compositions comprising these hscs, methods of using these modified hscs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified hscs or pge2-stimulated hscs express the surface marker, programmed cell death-1 ligand 1 (pd-l1)..
The Children's Medical Center Corporation

Antisense oligonucleotide inhibiting ß2gpi expression

The present invention aims to provide a novel nucleic acid capable of suppressing expression of β2gpi, as well as a pharmaceutical composition for the prophylaxis or treatment of diseases associated with β2gpi expression. The present invention solves the above-mentioned problem by providing an antisense oligonucleotide having a β2gpi expression suppressive activity, a pharmaceutical composition containing the antisense oligonucleotide, and a prophylactic or therapeutic drug for autoimmune diseases including aps, sle and the like, and thrombosis in hemodialysis that contains the antisense oligonucleotide and suppresses β2gpi expression..
Kyowa Hakko Kirin Co., Ltd.

Anti-semaphorin 3a antibody and treatment of alzheimer's disease and inflammatory immune diseases using same

The present invention mainly addresses the problem of providing an antibody against semaphorin 3a protein, said antibody enabling effective prevention and/or treatment of a disease, in which sema 3a protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. Or disseminated intravascular coagulation syndrome.
Chiome Bioscience Inc.

Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula i, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the janues kinase, fgfr kinase, flt3 kinase and src family kinase..
Guangzhou Maxinovel Pharmaceuticals Co., Ltd.

Heterocyclic compounds and use thereof

Heterocyclic compounds of formula (i) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds.
National Health Research Institutes

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Anti-nkp46 antibodies, toxin conjugates, and therapeutic use of same

An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (cdr) amino acid sequences as set forth in heavy chain ordered n to c terminus: seq id nos: 4, 6 and 8, and light chain ordered n to c terminus: seq id nos: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed.
University Of Rijeka Faculty Of Medicine

Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives

The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell lymphoma).
Eutropics Pharmaceuticals, Inc.

Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.

Device, managing treatment of an inflammatory autoimmune disease of a person

The present invention relates to a device, system and method for managing treatment of an inflammatory autoimmune disease of a person. The proposed device comprises an input unit (20) for receiving measurement data acquired over time including white blood cell count data related to the person's white blood cell count, tumor necrotic factor-α data related to the person's tumor necrotic factor-α, c-reactive protein data related to the person's c-reactive protein, cortisol level data related to the person's cortisol level and melatonin data related to the person's melatonin concentration.
Koninklijke Philips N.v.

B cell activation inhibitor, and therapeutic agent for autoimmune diseases

The inventors found that b cell activation is suppressed by tgf-β3 produced by lag3+ treg. They also discovered a b cell activation suppressor which contains tgf-β3 or a molecule having a tgf-β3 function, and a therapeutic agent for autoimmune diseases..
Chugai Seiyaku Kabushiki Kaisha

Bicyclic alkyne derivatives and uses thereof

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g.
Agency For Science, Technology And Research

Pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics Llc

Sulfinylphenyl or sulfonimidoylphenyl benzazepines

Wherein x and r1 to r6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Compositions and methods for treatment of autoimmune and other disease

Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.

Methods of treating cancer, infectious disease, and autoimmune disease using cxc chemokines

The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using cxc chemokines and the receptors to which they agonize. It has been found that certain chemokines, including cxcl4, cxcl9, cxcl10, and cxcl12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention..
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery

Nanocarriers and their processing for diagnostics and therapeutics

The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis..
Rhode Island Hospital

Exosomes for delivery of therapeutic agents

The present invention provides exosomes as drug delivery vehicles, compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to a specific patient tissue or organ. The present invention also provides methods of treating a disease, disorder, or condition such as cancer, an inflammatory disease, an infectious disease, an allergic disease, or an autoimmune disease, comprising administering to a patient in need thereof a provided therapeutic-loaded exosome or a pharmaceutical composition thereof..
Puretech Health Llc

Inhibitors of dek protein and related methods

The present invention provides methods of treatment using inhibitors of dek protein and dek activity. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which dek has been implicated.
The Regents Of The University Of Michigan

Compositions and methods related to multimodal therapeutic cell systems for autoimmune indications

The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease..
Rubius Therapeutics, Inc.

Bispecific antibodies that neutralize tnf-alpha and il-6: novel therapeutic agents for autoimmune disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-tnf-α antibody or antigen-binding fragment thereof and at least one anti-il-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a dnl® complex.
Ibc Pharmaceuticals, Inc.

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services

Immunoglobulin constant region fc receptor binding agents

Ivig replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function.
Gliknik Inc.

Cyclic di-nucleotides as modulators of sting

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants..

Chiral diaryl macrocycles as modulators of protein kinases

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Heteroaryl substituted aminopyridine compounds

Disclosed are compounds of formula (i) or salts thereof, wherein het is a heteroaryl selected from pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3 d]pyrimidinyl, pyrazolo[3,4 b]pyridinyl, pyrazolo[3,4 d]pyrimidinyl, imidazolo[4,5 b]pyridinyl, and imidazolo[4,5 d]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of formula (i) by a nitrogen ring atom in said heteroaryl and wherein said heteroaryl is substituted with zero to 2 rb; a is pyrazolyl, imidazolyl, triazolyl, isoxazolyl, oxadiazolyl or dihydroisoxazolyl, each substituted with zero or 1 ra; and r3, ra, and rb are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders

The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (compound 1) in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).. .
Arena Pharmaceuticals, Inc.

Human antibodies to pd-1

The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1.
Regeneron Pharmaceuticals, Inc.

Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (odn) sequence conjugated to a short-activating rna (sarna) or an antisense oligonucleotide sequence (aso), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating cebpa, and method of reducing activity of stat transcription factor, by one of the disclosed compounds or compositions.. .
City Of Hope

Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

The present specification provides immunosuppressive tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease.. .
Pin Pharma, Inc.

Compositions and methods for diagnosis and treatment of inflammation

Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions related to inflammation, including anemia of chronic disease, insulin resistance, metabolic syndrome, autoimmune disease, hypertension, diabetes, nonalcoholic fatty liver disease, cardiovascular disease, cancer, aging, neurodegenerative diseases, including alzheimer's disease and other forms of dementia, and other related conditions, and other related conditions.. .
The United States Of America As Represented By The Secretary Of The Navy

Fcrn antagonists and methods of use

Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Heteroaryl substituted aminopyridine compounds

Disclosed are compounds of formula (i) or salts thereof, wherein: het is a heteroaryl selected from imidazo[1,2-b]pyridazinyl and pyrazolo[1,5-a]pyrimidinyl, wherein said heteroaryl is attached to the pyridinyl group in the compound of formula (i) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 rb; a is pyrazolyl, imidazolyl, or triazolyl, each substituted with zero or 1 ra; and r3, ra, and rb are define herein. Also disclosed are methods of using such compounds as modulators of irak4, and pharmaceutical compositions comprising such compounds.
Bristrol-myers Squibb Company

Ceacam1 mediated protective immunity

The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..

Nanoparticle-based antigen specific immunotherapy

The present invention provides a nano particle comprising: a core comprising metal atoms; a corona comprising a plurality of ligands covalently linked to the core, wherein said plurality of ligands comprises: at least one carbohydrate ligand; at least one glutathione ligand; and at least one autoantigen peptide ligand. Also provided are compositions and vaccines comprising the nanoparticles, methods for producing the nanoparticles and medical uses of the nanoparticles, including for antigen specific imunotherapy of an autoimmune disease, such as diabetes mellitus type 1, in a mammalian subject..
Institut National De La Sante Et De La Recherche Medicale

Therapeutic antibodies and their uses

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease).
Pfizer Inc.

Therapeutic cd47 antibodies

Provided are anti-cd47 monoclonal antibodies (anti-cd47 mabs) with distinct functional profiles as described herein, methods to generate anti-cd47 mabs, and to methods of using these anti-cd47 mabs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of cd47 in tissue samples.. .
Tioma Therapeutics, Inc.

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Pharmaceutical compositions for treating, mitigating or preventing multiple sclerosis, autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described..
Eton Pharmaceuticals, Inc.

Immune cell trapping devices and methods for making and using the same

Embodiments herein described provide devices for identifying and collecting rare cells or cells which occur at low frequency in the body of a subject, such as, antigen-specific cells or disease-specific cells. More specifically, the devices are useful for trapping immune cells and the devices contain a physiologically-compatible porous polymer scaffold, a plurality of antigens, and an immune cell-recruiting agent, wherein the plurality of antigens and the immune cell recruiting agent attract and trap the immune cell in the device.
President And Fellows Of Harvard College

Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies

The present invention concerns compositions and methods of use of anti-hla-dr antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease.
Immunomedics, Inc.

Chimeric antigen receptors (cars), compositions and methods thereof

The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject..
Icell Gene Therapeutics Llc

Inhibitors of leukotriene a4 hydrolase

The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.

Compounds for the modulation of myc activity

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject..
Syros Pharmaceuticals, Inc.

Substituted anilines as ccr(4) antagonists

Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Treatment of autoimmune diseases with deep brain stimulation

Techniques using electrical stimulation for treating an autoimmune disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation.
Aleva Neurotherapeutics

Methods to treat diseases with protein, peptide, antigen modification and hemopurification

The current invention discloses methods to modify protein and peptide and antigen to treat disease such as pathogen infection, autoimmune diseases and cancer. The method involves increasing the molecular weight of the protein by connecting multiple peptide units with site specific conjugation to extend the in vivo half life.

Methods of obtaining mononuclear blood cells and uses thereof

Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection..
Biolinerx Ltd.

Estriol therapy for treatment of multiple sclerosis

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period..
The Regents Of The University Of California

New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery

. .

Crystalline forms of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Pyrrolopyrimidine compounds and their uses

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
Astex Therapeutics Ltd.

Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Apo-t B.v.

Composition and uses thereof

The invention relates to compositions comprising pinus pinaster stem bark extract, papain, and aloe vera extract, and methods of manufacturing same. There are also described methods of treating or preventing a variety of conditions, including treating or preventing elevated blood glucose, pre-diabetes, type 2 diabetes, autoimmune diseases, reducing or decreasing inflammation, treating or preventing diseases characterised by elevated levels of inflammation, and lowering blood cholesterol, said methods comprising administering an effective amount of a composition according to the invention to a subject in need thereof.
Arborvitae Health And Wellbeing Pty. Ltd.

Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease

The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.. .

Fused bicyclic pyrimidine derivatives and uses thereof

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.

Monomeric cxcl121 peptide and use thereof

The present invention provides a cxcl121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and hiv/aids.. .
The Medical College Of Wisconsin, Inc.

Novel tlr4 antagonist

The present disclosure relates to a peptide for inhibiting a tlr4 signaling pathway, a tlr4 antagonist including the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. More specifically, the present disclosure relates to a peptide which binds to a tlr4/md2 composite to inhibit the secretion of interleukin-6 (il-6), no, and ros, and the activation of nfκb and mapks, a tlr4 antagonist including the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases.
Ajou University Industry-academic Cooperation Foundation

Novel proteins specific for cd137

The present disclosure provides human lipocalin muteins that bind cd137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making cd137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins.
Pieris Pharmaceuticals Gmbh

Rigel Pharmaceuticals, Inc.

. .

Methods and compositions for the treatment of cancer or other diseases

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
City Of Hope

Composition enriched in anti-a and/or anti-b polyclonal immunoglobulins for use in the treatment of autoimmune diseases or polycythemia

The invention relates to a composition strongly enriched with anti-a and/or anti-b polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-a or anti-b polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and/or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Therapeutic cd47 antibodies

Provided are anti-cd47 monoclonal antibodies (anti-cd47 mabs) with distinct functional profiles as described herein, methods to generate anti-cd47 mabs, and to methods of using these anti-cd47 mabs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of cd47 in tissue samples.. .
Tioma Therapeutics, Inc.

Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof

The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases. In particular, the present invention provides a multispecific antibody, or an antigen binding fragment thereof, comprising at least two different domains specifically binding to at least two different, non- overlapping sites in a cytokine and an fc moiety.
Institute For Research In Biomedicine

Autotaxin inhibitors and uses thereof

Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases)..
National And Kapodistrian University Of Athens

Compounds and treating autoimmune diseases

Wherein x and y independently are o or nr1; each r1 is independently h or c1-c6 alkyl; ring a is aryl; each r2 independently is h, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two r2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; r3 and r4 independently are h or c1-c6 alkyl; and r5 is halo, cyano, or c1-c6 alkyl.. .

Targeted nanocarriers for targeted drug delivery of gene therapeutics

A targeted nanocarriers also termed nanomedicines and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme such as a zinc finger nuclease, a crispr/cas system, or a talen) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microrna, a sirna, a mrna, an antisense oligonucleotide, or a sense oligonucleotide) to a range of mammalian cell species. Cell specific targeting is achieved by using nanocarriers featuring suitable targeting anchors having a targeting moiety that can be a carbohydrate, an antibody or an antibody fragment, a non-antibody protein derivative, an aptamer, a lipoprotein or a fragment thereof, a peptidoglycan, a lipopolysaccharide or a fragment thereof, or a cpg dna.
Rodos Biotarget Gmbh

Composition for preventing or treating autoimmune disease, containing ssu72 as active ingredient

The present disclosure relates to a composition for preventing or treating an autoimmune disease, in which the composition includes ssu72 as an active ingredient. According to the present invention, ssu72 has an effect of effectively inhibiting stat3 activity, thereby effectively preventing and treating, ultimately, an immune disease, and preferably, stat3-mediated diseases through an action capable of inhibiting the expression of inflammatory cytokines when ssu72 is overexpressed and simultaneously promoting the expression of il-4 and il-10, which are factors associated with immunoregulatory t cells..
The Catholic University Of Korea Industry- Academic Cooperation Foundation

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.

Nanoparticle conjugates and uses thereof

The targeted delivery of therapeutic agents to specific cells remains a challenge in drug delivery. Provided herein are nanoparticle-targeting agent conjugates that can be used for the targeted delivery of therapeutic agents to certain cells and target tissues.
Massachusetts Institute Of Technology

Compositions comprising bacterial strains

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.. .
4d Pharma Research Limited

Therapeutic ozone agent and treatment

The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

A predicting the risk of incidence of chronic kidney diseases

The present invention relates to means and methods suitable for risk prediction of chronic kidney disease (ckd) using pro-enkephalin or fragments thereof as biomarker. The risk prediction methods of the invention are intended for healthy subjects and for subjects suffering from diseases such as hypertension, cardiovascular diseases and events, diabetes, metabolic syndrome, obesity, or autoimmune diseases.
Sphingotec Gmbh

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin

Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the t cell immunoglobulin and mucin protein-3 (hm-3). The invention provides a tim-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Wherein r1a, r1b, r2, r4, r5, r6, r7, r8, w, x, y, z, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

Inhibitors of leukotriene a4 hydrolase

Pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists

Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
Chemocentryx, Inc.

Il-2 variants for the treatment of autoimmune diseases

This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an il-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles.
Delinia, Inc.

Probiotic compositions for improving metabolism and immunity

The application relates to methods based on modulating mammalian intestinal microbiota and related probiotic and prebiotic compositions. Specifically, the application relates to the use of novel bacterial genera ileibacterium and dubosiella, including their species i.
New York University

Takeda Pharmaceutical Company Limited

. .

T-reg cell expansion

This invention relates to methods of expanding t regulatory cells through ox40l and jagged-1 induced signaling. The methods can be used for treating autoimmune diseases..
The Board Of Trustees Of The University Of Illinois

Compositions and methods for diagnosing and treating autoimmune diseases

Disclosed are compositions and methods for detecting, isolating, and/or characterizing a t cell or autoantibody associated with type i diabetes. The composition and methods comprise the use of a hybrid insulin peptide having an n-terminal amino acid sequence taken from the human insulin peptide and a c-terminal amino acid sequence taken from a secretory granule protein that are joined through a peptide bond to form an autoimmune antigen.
The Regents Of The University Of Colorado, A Body Corporate

Imidazo isoindole derivative, preparation method therefor and medical use thereof

The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (i), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the ido-mediated tryptophan metabolic pathways.
Shanghai Hengrui Pharmaceutical Co., Ltd.

Inhibitors of leukotriene a4 hydrolase

The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.

Heterocyclic derivatives modulating activity of certain protein kinases

The present invention relates to novel heterocyclic derivatives having general formula (i) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like alzheimer's or parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (i) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications..
Universita' Degli Studi Di Milano

Small molecule compounds targeting pbx1 transcriptional complex

In accordance with one or more embodiments, the present invention provides a compound of formulas i, ii, and iii, for use in methods of inhibition of pbx1-dna interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.. .
The Johns Hopkins University

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Substituted hydroxystilbenes and their therapeutic applications

It discloses a compound of formula i that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.. .
Resolvex Pharmaceuticals Inc.

Covalent conjugates of bet inhibitors and alpha amino acid esters

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. .
Glaxosmithkline Intellectual Property Development Limited

Insulin mimotopes and methods of using the same

Methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that induces conversion of naive t cells into foxp3+ regulatory t cells to induce immunosuppression in the subject. Methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease, particularly type 1 diabetes..
National Jewish Health

Methods of preventing and treating autoimmunity

Methods of preventing, treating or ameliorating autoimmune diabetes by modulating the binding of mhc class ii molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of methyldopa. Pharmaceutical compositions containing therapeutically effective amounts of methyldopa in extended release formulations and methods of using the same are also provided..
The University Of Florida Research Foundation Incorporated

Methods for the treatment and prevention of inflammatory diseases

The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from helicobacter pylori activates nkt cells in a cd1d-restricted fashion, and is protective against ahr in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by nkt cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative nkt cells and foxp3+ treg cells.
Children's Medical Center Corporation

Heterocyclic compounds and their uses

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.

Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical compostion for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting pi3 kinases, thereby being useful in preventing or treating pi3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases..
Korea Research Institute Of Chemical Technology

Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof

The present invention provides compounds pounds of formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i), (ii) or (iii) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (phgdh) in a subject, such as proliferative diseases (e.g., cancers (e.g., breast cancer, er negative breast cancer, melanoma, cervical cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases).
Dana-farber Cancer Institute, Inc.

Therapeutic pooled blood apoptotic cell preparations and uses thereof

Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis.
Enlivex Therapeutics Ltd.

Nissan Chemical Industries, Ltd.

. .

Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnostics Hybrid, Inc.

Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid

The present invention relates to novel solid crystal forms of pomalidomide named form b, form m, pomalidomide:gentisic acid co-crystal and their preparation. Advantageously, these solid forms are used in pharmaceutical compositions for the treatment and the prevention of multiple myeloma, of inflammatory diseases, of autoimmune diseases, of immune diseases, of myelodysplastic syndrome, of myeloproliferative disorders, of anemia, of scleroderma, amyloidosis or of other diseases associated with unwanted angiogenesis..
F.i.s. - Fabbrica Italiana Sintetici S.p.a.

Treatment of autoimmune disease

Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole pkc inhibitors..
Mingsight Pharmaceuticals, Inc.

Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease

Compositions and methods for measuring c-peptide binding by cells, including cells expressing glut1, using a c-peptide binding facilitator, such as an albumin. Such methods include incubating the cell with a known amount of c-peptide and a c-peptide binding facilitator, and determining the amount of c-peptide bound to the incubated cells.
Board Of Trustees Of Michigan State University

Antibodies directed against interleukin 36 receptor (il-36r)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (il-36r). The invention provides an il-36r-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to human antibodies against human interleukin 2 (il-2) and methods of use of such antibodies for modulating il-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.. .
Musc Foundation For Research Development

Methods and reagents to treat autoimmune diseases and allergy

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen.

Methods of treating immune disorders using pd-1 binding proteins

Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. .
Celgene Corporation

Ldl quantitation and methods of use

The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy.

Anti-cd303 monoclonal antibodies

The invention relates to chimeric or humanised anti-cd303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (bpdcn) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.. .
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Cgas in systemic lupus erythematosus (sle)

The present invention provides therapeutic strategies for treatment of severe debilitating diseases associated with ifn-i due to cgas activation. In one aspect, the invention provides compounds of formula (i): [formula should be inserted here] and pharmaceutical uses thereof.
University Of Washington

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.. .
Orbital Atk, Inc.

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.

Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system

The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of cns autoimmune diseases, or for the preparation of a pharmaceutical composition for treating cns autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of cns autoimmune diseases.
Hadasit Medical Research Services & Development Limited

Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Glaucocalyxin a derivative and preparation method and application thereof

Provided is a glaucocalyxin a derivative, or salt thereof, as represented by the formula (i), a method for preparation of said glaucocalyxin a derivative, and a use for said glaucocalyxin a derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. Difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer.
Suzhou Pharmavan Cancer Research Center Co., Ltd.

Exosomes sourced from granulocytic myeloid-derived suppressor cells and application thereof

Provided are exosomes sourced from a granulocyte myeloid-derived suppressor cell and an application thereof. The exosomes are named as g-mdsc exo.
Jiangsu University

Novel compound useful for the treatement of degenerative and inflammatory diseases

A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide

A method of reducing pathogenic t-helper cell activity in a human subject in need thereof is disclosed. The method comprises administering to the human subject, known to have a condition mediated by one or more differentiated t-helper cells responsive to cd51, an effective amount of a nitroxide antioxidant, where the nitroxide antioxidant increases cd51 expression, thereby reducing pathogenic t-helper cell activity.

Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

The present invention relates to the field of immunotherapy, in particular, to adoptive t cell therapy, t cell receptor (tcr) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the tcr alpha chain construct (tra) and tcr beta chain construct (trb) of a tcr construct specific for an epitope from an antigen presented on major histocompatibility complex (mhc), comprising contacting t cells isolated from a donor with a library of artificial antigen presenting cells (apc) comprising cells expressing all mhc i or mhc ii alleles present in the donor, preferably, in k562 cells.
Helmholtz Zentrum MÜnchen-deutsches Forschungszentrum FÜr Gesundheit Und

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms..
Rigel Pharmaceuticals, Inc.

Co-crystals of a bruton's tyrosine kinase inhibitor

Disclosed are co-crystals of the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the co-crystals, as well as methods of using co-crystals, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclic Llc

Solvated forms of a bruton's tyrosine kinase inhibitor

Described herein are solvates of the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the solvates, as well as methods of using the solvates, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

18f-labelled folates as pet radiotracers

The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein fluorine-18 is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of therapy of cancer and inflammatory and autoimmune diseases.. .
Merck & Cie

Heterocyclic compounds useful as inhibitors of tnf

Disclosed are compounds of formula (i) or a salt thereof, wherein: x is cr6 or n; w is: (i) —(cr3r3)1-4— or (ii) —(cr3r3)x-y—(cr3r3)y-; and y, r1, r2, r3, r5, r6, r7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of tnfα, and pharmaceutical compositions comprising such compounds.
Bristol-myers Squibb Company

Treatment of ocular inflammatory diseases using laquinimod

Disclosed is a method for treating an ocular inflammatory disease (oid), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
Teva Pharmaceutical Industries, Ltd.

Pglyrp2 biomarker in idiopathic pneumonia syndrome

A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.. .
Case Western Reserve University

Detection of t cell exhaustion or lack of t cell costimulation and uses thereof

The application relates to methods of assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and the use of such methods in determining an individual's risk of autoimmune disease progression, progression of a chronic infection, not responding to a treatment for a chronic infection, not mounting an effective immune response to vaccination, infection-associated immunopathology, transplant rejection, or cancer progression. The application also relates to in vitro methods for assessing whether cd8+ and cd4+ t cells in a sample have an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and for identifying a substance capable of inducing an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype in an individual, as well as a kit for assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype or whether an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype is present in a sample of cd8+ and cd4+ t cells..
Cambridge Enterprise Limited

Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody

Tumor necrosis factor-α (tnfα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of tnf production is implicated in a variety of human diseases including alzheimer's disease, cancer, major depression, and inflammatory bowel disease.
Dnx Biotech, Llc

Mutant hsp70i to prevent autoimmune disease

Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising dna encoding a variant inducible heat shock protein 70 (hsp70i) having a mutation in the dendritic cell binding region thereof (hsp70i435-447) or an isolated variant gene product in the form of hsp70i with a modification in the dendritic cell activating region thereof (hsp70i435-447).. .
Loyola University Of Chicago

Compositions and methods for suppressing or reducing systemic immune response in a subject

The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof..
The Trustees Of The University Of Pennsylvania

Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions

The invention features all-trans retinoic acid (atra)-related compounds capable of associating with pin1 and methods of treating a proliferative disorder characterized by elevated pin1 marker levels, pin1 degradation, and/or reduced pin1 ser71 phosphorylation in a subject by administering an atra-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated pin1 marker levels) by administering an atra-related compound in combination with another therapeutic compound..
Pinteon Therapeutics, Inc.

Synthesis and utility of new capgroup largazole analogs

Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and alzheimer's disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein.
University Of Notre Dame Du Lac

1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof

Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Methods of using chimeric receptors to identify autoimmune disease

The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnostic Hybrids, Inc.

Antibody polypeptides that antagonize cd40l

Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited

Bcr-complex-specific antibodies and methods of using same

This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
King's College London

Crystal form of jak inhibitor and preparation method thereof

The present disclosure relates to novel crystalline forms of jak inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis.
Crystal Pharmatech Co., Ltd

Method of treating transplant rejection and autoimmune diseases

A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of su-5416 is disclosed.. .
Wisconsin Alumni Research Foundation

Treatment of autoimmune disease in a patient receiving additionally a beta-blocker

The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.. .
Novartis Ag

Genetically modified mesenchymal stem cell expressing klotho

A genetically modified mesenchymal stem cell (msc) includes an exogenous nucleic acid that includes a klotho encoding region operably linked to a promoter or promoter/enhancer combination. The mscs can be used for the treatment of cancer, organ fibrosis, renal failure, age-related changes of organs or organ systems, arteriosclerosis, and neurodegenerative diseases, such as alzheimer's disease (ad), multiple sclerosis (ms), huntington's disease, amyotrophic lateral sclerosis (als), parkinson's disease, and schizophrenia, as well as dementia, diabetes mellitus, sepsis and autoimmune diseases and autoimmune-related diseases..
Apceth Gmbh & Co. Kg

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein using a linker. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Purinone compounds as kinase inhibitors

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Urea derivatives and uses thereof

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.

Devices for detection of antibodies against therapeutic drugs

Devices for detection of antibodies against therapeutic drugs (adas), in which chimeric proteins facilitate immobilization and exposure of target epitopes, are described. Results can be obtained in minutes, enabling point of care testing and/or patient self-testing, and risk assessment.

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases..
University Of Southern California

Inhibitors of bruton's tyrosine kinase

Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics Llc

Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life

Methods and pharmaceutical compositions for preventing and/or treating acute and chronic inflammation and autoimmune diseases are provided herein. Tumor necrosis factor-α (tnfα) promotes an inflammatory response, which causes clinical problems associated with inflammation and autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma.
Dnx Biotech, Llc

Cell-based composition and use thereof for treatment of psoriasis and autoimmune diseases

A method for the treatment of psoriasis or an autoimmune disease in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml.. .
Cytopeutics Sdn. Bhd.

Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc

Monitoring health and disease status using clonotype profiles

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Beekenkamp Plants B.v.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .
Beekenkamp Plants B.v.

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Fused-ring compounds, pharmaceutical composition and uses thereof

This disclosure is related to a fused-ring compound of formula (i) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (i) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (ido) and/or tryptophan 2, 3-dioxygenase (tdo). This disclosure further provides methods of treating ido and/or tdo-associated diseases, including cancer, viral infection and autoimmune diseases..
Shanghai De Novo Pharmatech Co., Ltd.

Marker sequences for the diagnosis and stratification of systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; ssc) and the markers identified with the aid of this method, which can differentiate between ssc and other autoimmune diseases on the one hand and between different ssc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of ssc.
Protagen Ag

Fcrn antibodies and methods of use thereof

The present invention features antibodies that have high binding affinity to human neonatal fc receptor (fcrn). These anti-fcrn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject..
Momenta Pharmaceuticals, Inc.

Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

The present application discloses a novel fusion peptide of il-2 and il-33 and its use. It comprises a biologically active domain of interleukin-2 (il-2) or a biologically active fragment or homolog thereof, and a biologically active domain of interleukin-33 (il-33) or a biologically active fragment or homolog thereof.
University Of Virginia Patent Foundation

Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.
The Board Of Trustees Of The Leland Stanford Junior University

Tgr5 modulators and methods of use thereof

Or a salt, solvate, hydrate, or prodrug thereof. The compounds of formula a are tgr5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease..

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

Pyridinyl and fused pyridinyl triazolone derivatives

Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk..

Markers of alzheimers disease

The use of markers that participate in inflammatory processes and are associated cytokines in the diagnosis, treatment or prophylaxis of diseases is disclosed. Specifically, cytokines are used to diagnose or treat non-neoplastic or non-leukaemic diseases such as autoimmune diseases or neurodegenerative disorders by the process of taking a dna bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the snp loci at positions −1082, −819 and −592 of the gene encoding il-10.
Immunoclin Ltd.

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof

The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hes-mscs are characterized at least in part by the low level of expression of il-6.
Imstem Biotechnology, Inc.

Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting

The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.

Heterocyclic compounds as pi3k-y inhibitors

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Heterocyclic compounds and use thereof

Heterocyclic compounds of formula (i) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation.
National Health Research Institutes

Quinazoline and quinoline compounds and uses thereof

This invention provides compounds of formula (i) or a pharmaceutically acceptable salt thereof, wherein t, j, r, r4, rq, o, ra, w and rb and subsets thereof are as described in the specification. The compounds are inhibitors of nampt and are thus useful for treating cancer, inflammatory conditions, and/or t-cell mediated autoimmune disease..
Millennium Pharmaceuticals, Inc.

Inhibitors of trka kinase

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited

Covalent inhibitors of cdk-7

Wherein r0, r1, r2, r3, r4, r5, and l are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds..

Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .

Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd

The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“ra”). The method is used in assessing ra in vitro.
Roche Diagnostics Operations, Inc.

Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Novel compound useful for the treatment of degenerative and inflammatory diseases

A novel compound able to inhibit jak is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6.. .
Galapagos Nv

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Or a salt thereof, wherein r1, r2, r3, r4, r5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds.